perfluorohexyloctane
Trade name: Miebo
Small moleculeapproved
Approved
May 18, 2023
Clinical trial activity
7 trials · 3 clinical orgs · 2 marketing orgs
Phase 1
0
Phase 2
5
Phase 3
4
Phase 4
2
Earliest trial started Jan 3, 2018 (NCT03333057)
Timeline
2010s
- Jan 1, 2018
Earliest Phase 2 Sponsor(trial)
2020s
- Jan 1, 2020
Earliest Phase 3 Sponsor(trial)
- May 18, 2023
Bausch Health Companies — Earliest FDA Approval
- May 18, 2023
Bausch & Lomb — Marketing Organization
- May 18, 2023
Bausch Health Companies — NDA Secondary Org
- May 18, 2023
Bausch Health Companies — NDA Organization
Indications
Approved for
Mechanism of action
- Unspecified targetOTHER
Unknown
- Unspecified targetUnclear
unclear
Approval history
- approvedMay 18, 2023
Chemistry & pharmacology
Loading structure…
SMILES
CCCCCCCCC(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)F- Mol. weight
- 432.26 g/mol
- Lipinski Ro5
- 1 violation(s)
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
- Delivery
- Topical
- Availability
- Prescription Only
Oral
No
Parenteral
No
Topical
Yes
First in class
Sources
- ChEMBLCHEMBL5314588 ↗
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07054606 | Phase 4 | Jul 2, 2025 | Bausch & Lomb |
| NCT05723770 | Phase 4 | Nov 3, 2023 | Bausch & Lomb |
| NCT05515471 | Phase 3 | Feb 4, 2021 | Hengrui Therapeutics, Inc. |
| NCT04567329 | Phase 3 | Nov 18, 2020 | Bausch & Lomb |
| NCT04140227 | Phase 3 | Feb 29, 2020 | Novaliq GmbH |
| NCT04139798 | Phase 3 | Jan 31, 2020 | Novaliq GmbH |
| NCT03333057 | Phase 2 | Jan 3, 2018 | Novaliq GmbH |
Showing 7 of 7 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Bausch & Lomb | For profit | 3 | 3 | 2 | 2020 |
| Novaliq GmbH | For profit | 3 | 3 | 2 | 2018 |
| Hengrui Therapeutics, Inc. | For profit | 1 | 1 | 1 | 2021 |
3 organizations
Page 1 / 1
Marketing (3)
| Organization | Org type | Relationship | Date |
|---|---|---|---|
| Bausch & Lomb | For profit | MKTG | May 18, 2023 |
| Bausch Health Companies | For profit | NDA2 | May 18, 2023 |
| Bausch Health Companies | For profit | NDA | May 18, 2023 |